AbbVie Resolves Humira (adalimumab) Litigation with Boehringer Ingelheim
Shots:
- AbbVie has resolved the Humira litigation with BI- granting BI non-exclusive rights to BI for Humira’s IPR in the US
- BI will pay royalties for licensing HUMIRA patents and acknowledges the validity and enforceability of the licensed patents
- The initiation of the license will begin from Jul-1 2023
Ref: AbbVie| Image: AbbVie
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
